On the afternoon of February 18, the Guangdong provincial government held a press conference on the latest developments in the epidemic situation and the state of progress in the development of new therapies against the novel coronavirus. In discussing the use of traditional Chinese medicine in treating pneumonia caused by the novel coronavirus, Professor Yang Zifeng of the Guangzhou Institute of Respiratory Health said that 5 traditional Chinese medicines, including liushen capsules and pills, have demonstrated the ability to suppress the novel coronavirus in in vitro experiments. In addition, Professor Zhong Nanshan, academician at the Chinese Academy of Engineering, added that traditional Chinese medicines such as liushen capsules and pills are already commonly dispensed in clinical settings, and have been shown to inhibit the entry of viruses into human cells and reduce runaway inflammation, propositions that are also supported by experimental evidence. This provides support and guidance for the use of traditional Chinese medicine in clinical treatment of COVID-19 patients.
The announcement of research demonstrating the positive effects of traditional Chinese medicine is undoubtedly good news for the treatment of pneumonia caused by the novel coronavirus. These research outcomes also suggest new approaches to treatment plans. Traditional Chinese medicine is a treasure of the Chinese people that has been handed down for millennia, where countless formulas and medicines have been discovered and handed down over the course of treating the various epidemics and plagues that have broken out in history. As one of the mainstay medicines used to treat febrile diseases, Leiyunshang Pharmaceutical Group Co.,Ltd. (hereinafter “Leiyunshang Pharmaceutical”) liushen capsules and pills have an even greater role to play in these trying times.
After the press conference, several authoritative media outlets reported on the key points covered:
A special program by CCTV13 on the fight against the novel coronavirus outbreak reported that experts have said that traditional Chinese medicines such as liushen capsules and pills are already commonly used in clinical treatment of pneumonia caused by the novel coronavirus. Traditional Chinese medicines have been shown to reduce entry of viruses into human cells and alleviate symptoms of inflammation, providing further evidence for the use of traditional Chinese medicines in such clinical settings.
In a special live broadcast program by Suzhou Broadcasting System on the fight against the novel coronavirus, correspondents contacted executives at Leiyunshang Pharmaceutical to further explore the anti-inflammatory and anti-viral effects of liushen capsules and pills.
Pharmaceutical enterprises should fulfil their social responsibilities during this key period in the fight against the novel coronavirus outbreak. Apart from vigorously pursuing scientific research, Leiyunshang Pharmaceutical has also resumed operations and production as required by local governments while adhering to the strictest epidemic prevention and control measures, thus establishing a “line of defense” for safe production and the saving of human lives. During the Spring Festival, which fell within the outbreak period, all members of Leiyunshang Pharmaceutical came together to overcome labor and raw material shortages, doing their all to ensure adequate epidemic prevention and control supplies. The Suzhou Daily also ran a prominent story on efforts by Leiyunshang Pharmaceutical to safeguard the flow of supplies.
Huadong Medicine Entered the Directory of “the Best Listed Companies of New Fortune”
Grand Real Estate Guiyang Acquired a High-quality Land Parcel in Guanshanhu District, Guiyang at the price of RMB 1.34 Billion
The exceptional performance of “Grand Bay Hotel” with the Support of the 618 Shopping Event
Grand Bay Hotel Beijing Had Its First Online Live Show By Exploring New Marketing Models
Grand Shopping Center Innovated Marketing Models to Promot Digital Transformation
Grand Pharma Shortlisted for the Third “New Fortune Best IR of Hong Kong Listed Company” Award